David's PhD in pharmacology was sponsored by Pfizer. He has more than 30 years experience in drug discovery and development in roles covering preclinical pharmacology, drug metabolism & pharmacokinetics and clinical pharmacology. He has worked on antiviral projects for HIV for Roche and has anti-infective experience in antiparasitic, antifungal and antibiotic drug discovery. As Eisai's Global Head of Clinical Pharmacology he supported many new drug approvals including diethylcarbamazine (WHO), rufinamide, perampanel, zonisamide, lenvatinib and eribulin, as well as approvals for cannabidiol for the treatment of childhood epilepsy syndromes at GW.
